Results

598.

Maurer, M.⁺, Casale, T. B., Saini, S. S., Ben-Shoshan, M., Giménez-Arnau, A. M., Bernstein, J. A., Yagami, A., Stjepanovic, A., Radin, A., Staudinger, H. W., Patel, N., Amin, N., Akinlade, B., Fan, C., Bauer, D., Yancopoulos, G. D., Patel, K., Mannent, L. P., and Laws, E.: Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): two randomized, double-blind, placebo-controlled, phase 3 trials. J. Allergy Clin. Immunol. 2024: 154; 184-194. IF: TBD (IF 2023: 11.40)

600.

Hu, M., Scheffel, J., Frischbutter, S., Steinert, C., Reidel, U., Spindler, M., Przybylowicz, K., Hawro, M., Maurer, M., Metz, M.^*, and Hawro, T.^+*: Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas. Clin. Exp. Med. 2024: 24; 171. IF: TBD (IF 2023: 3.20)

601.

Casale, T. B.⁺, Trzaskoma, B., Holden, M., Bernstein, J. A., and Maurer, M.: Does angioedema in patients with chronic spontaneous urticaria impact response to omalizumab? World Allergy Organ. J. 2024: 17; 100943. IF: TBD (IF 2023: 3.90)

602.

Reshef, A.⁺, Buttgereit, T., Betschel, S. D., Caballero, T., Farkas, H., Grumach, A. S., Hide, M., Jindal, A. K., Longhurst, H., Peter, J., Riedl, M. A., Zhi, Y., Aberer, W., Abuzakouk, M., Al Farsi, T., Al Sukaiti, N., Al-Ahmad, M., Altrichter, S., Aygören-Pürsün, E., Baeza, M. L., Bara, N. A., Bauer, A., Bernstein, J. A., Boccon-Gibod, I., Bonnekoh, H., Bouillet, L., Brzoza, Z., Bygum, A., Calderon, O., de Albuquerque Campos, R., Campos Romero, F. H., Cancian, M., Chong-Neto, H. J., Christoff, G., Cimbollek, S., Cohn, D. M., Craig, T., Danilycheva, I., Darlenski, R., Du-Thanh, A., Ensina, L. F., Fomina, D., Fonacier, L., Fukunaga, A., Gelincik, A., Giavina-Bianchi, P., Godse, K., Gompels, M., Goncalo, M., Gotua, M., Guidos-Fogelbach, G., Guilarte, M., Kasperska-Zajac, A., Katelaris, C. H., Kinaciyan, T., Kolkhir, P., Kulthanan, K., Kurowski, M., Latysheva, E., Lauerma, A., Launay, D., Lleonhart, R., Lumry, W., Malbran, A., Ali, R. M., Nasr, I., Nieto-Martinez, S., Parisi, C., Pawankar, R., Piñero-Saavedra, M., Popov, T. A., Porebski, G., Prieto Garcia, A., Pyatilova, P., Rudenko, M., Sekerel, B. E., Serpa, F. S., Sheikh, F., Siebenhaar, F., Soria, A., Staevska, M., Staubach, P., Stobiecki, M., Thomsen, S. F., Triggiani, M., Valerieva, A., Valle, S., Van Dinh, N., Vera Ayala, C. E., Zalewska-Janowska, A., Zanichelli, A., Magerl, M., and Maurer, M.: The definition, acronyms, nomenclature, and classification of angioedema: AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus. J. Allergy Clin. Immunol. 2024: 154; 398-411. IF: TBD (IF 2023: 11.40)

603.

Mubariki, R., Samara, R., Giménez-Arnau, A. M., Maurer, M., Bejar, J., Toubi, E., and Vadasz, Z.⁺: CD4⁺CCR5⁺ T cells and CCL3⁺ mast cells are increased in the skin of patients with chronic spontaneous urticaria. Front. Immunol. 2024: 15; 1327040. IF: TBD (IF 2023: 5.70)

604.

Cherrez-Ojeda, I.⁺, Bousquet, J., Giménez-Arnau, A., Godse, K., Krasowska, D., Bartosińska, J., Szczepanik-Kułak, P., Wawrzycki, B., Kolkhir, P., Allenova, A., Allenov, A., Tkachenko, S., Teovska Mitrevska, N., Mijakoski, D., Stoleski, S., Kolacinska-Flont, M., Kuprys-Lipinska, I., Molinska, J., Kasperska-Zając, A., Zajac, M., Zamlynski, M., Mihaltan, F., Ulmeanu, R., Zalewska-Janowska, A., Tomaszewska, K., Al-Ahmad, M., Al-Nesf, M. A., Ibrahim, T., Aqel, S., Pesqué, D., Rodríguez-González, M., Wakida-Kuzunoki, G. H., Ramon, G. D., Ramon, G. N., Neisinger, S., Bonnekoh, H., Rukhadze, M., Khoshkhui, M., Fomina, D., Larenas-Linnemann, D., Košnik, M., Oztas Kara, R., Caballero López, C. G., Liu, Q., Ivancevich, J. C., Ensina, L. F., Rosario, N., Kvedariene, V., Ben-Shoshan, M., Criado, R. F. J., Bauer, A., Cherrez, A., Cherrez, S., Chong-Neto, H., Rojo-Gutierrez, M. I., Rudenko, M., Larco Sousa, J. I., Lesiak, A., Matos, E., Tinoco, I., Crespo Shijin, C., Hinostroza Logroño, R., Sagñay, J. C., Faytong-Haro, M., Robles-Velasco, K., Zuberbier, T., and Maurer, M.⁺: Usage prevalence of angioedema patient-reported outcome measures: results from the UCARE and ACARE PROMUSE study. J. Allergy Clin. Immunol. Pract. 2024: 12; 2211-2215. IF: TBD (IF 2023: 8.20)

605.

Ghazanfar, M. N.⁺, Petrosius, V., Sørensen, J. A., Zhang, D. G., Ali, Z., Maurer, M., Kocatürk, E., Nielsen, V. W., Savickas, S., Keller, U. A. D., Schoof, E. M., and Thomsen, S. F.: Plasma proteomics analysis of patients with chronic spontaneous urticaria reveals significant associations with key disease characteristics but not with response to omalizumab treatment. Allergy 2024: 79; 2547-2550. IF: TBD (IF 2023: 12.60)

606.

Maurer, M.⁺, Kolkhir, P.^*, Pereira, M. P.^*, Siebenhaar, F.^*, Witte-Händel, E., Bergmann, K.-C., Bonnekoh, H., Buttgereit, T., Fluhr, J. W., Frischbutter, S., Grekowitz, E. M., Herzog, L., Kiefer, L. A., Krause, K., Magerl, M., Muñoz, M., Neisinger, S., Nojarov, N., Prins, S., Pyatilova, P., Ramanauskaite, A., Scheffel, J., Terhorst-Molawi, D., Treudler, R., Weller, K., Zuberbier, T., and Metz, M.: Disease modification in chronic spontaneous urticaria. Allergy 2024: 79; 2396-2413. IF: TBD (IF 2023: 12.60)

587.

Buttgereit, T., Vera, C., Aykanat, S., Weller, K., Gutsche, A., Maurer, M.⁺, and Magerl, M.: The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center. Front. Immunol. 2024: 15; 1405317. IF: TBD (IF 2023: 5.70)